Riverview Capital Advisers’s Quest Diagnostics DGX Stock Holding History

Riverview Capital Advisers’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-6,069	Closed	-$1.16M	–	96
2025 Q3	$1.16M	Hold	6,069	–	–	0.33%	51
2025 Q2	$1.09M	Sell	6,069 -2,099	-26%	-$365K	0.31%	60
2025 Q1	$1.38M	Hold	8,168	–	–	0.43%	52
2024 Q4	$1.23M	Hold	8,168	–	–	0.37%	50
2024 Q3	$1.27M	Hold	8,168	–	–	0.39%	46
2024 Q2	$1.12M	Hold	8,168	–	–	0.38%	49
2024 Q1	$1.09M	Hold	8,168	–	–	0.37%	48
2023 Q4	$1.13M	Hold	8,168	–	–	0.43%	43
2023 Q3	$995K	Hold	8,168	–	–	0.44%	51
2023 Q2	$1.15M	Hold	8,168	–	–	0.5%	45
2023 Q1	$1.16M	Hold	8,168	–	–	0.5%	47
2022 Q4	$1.28M	Hold	8,168	–	–	0.69%	35
2022 Q3	$1M	Hold	8,168	–	–	0.63%	45
2022 Q2	$1.09M	Hold	8,168	–	–	0.6%	47
2022 Q1	$1.12M	Hold	8,168	–	–	0.51%	48
2021 Q4	$1.41M	Buy	+8,168	New	+$1.24M	0.63%	40

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Riverview Capital Advisers's DGX Position: Q4 2025 in Review

Riverview Capital Advisers sold out of Quest Diagnostics (DGX) in Q4 2025, closing a stake of 6,069 shares — an estimated $1.16M sold.

Riverview Capital Advisers first reported a position in DGX in Q4 2021 and held it in 16 quarters. The position peaked at $1.41M in Q4 2021. 1,050 funds tracked by Wall St. Rank hold DGX as of Q4 2025.

Riverview Capital Advisers reported no remaining Quest Diagnostics position as of Q4 2025 after selling out during the quarter.
Riverview Capital Advisers sold 6,069 Quest Diagnostics shares in Q4 2025, an estimated $1.16M.
Riverview Capital Advisers first reported a position in Quest Diagnostics in Q4 2021 and held it in 16 quarters.
Riverview Capital Advisers's Quest Diagnostics position peaked at $1.41M in Q4 2021.
1,050 funds tracked by Wall St. Rank held Quest Diagnostics as of Q4 2025.

Based on Riverview Capital Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.